Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Preventing Falls in People Aged Over 75 at High Risk of Falling Through Specific Rehabilitation Involving Walking Backwards (PCRetro)

10 czerwca 2026 zaktualizowane przez: Assistance Publique - Hôpitaux de Paris

Falls are a major health problem for people over 75 years old. Backward walking may strengthen the muscles of the legs, improve posture and balance, and make walking more stable, which could help prevent new falls and improve everyday movement.

This is an open-label, multicenter, randomized controlled trial that will examine whether backward walking, integrated to usual rehabilitation in a geriatric day hospital program, can help reduce the number of new falls in older adult at high risk of falling.

About 300 people aged over 75 years, living at home and at high risk of falling, will be included in this trial in 11 geriatric day hospitals in France. After receiving appropriate information, those who agree to participate will sign a written consent form and will then be randomly assigned to one of two groups. Both groups will receive standard rehabilitation care in the geriatric day hospital, with two rehabilitation sessions per week for 12 weeks. In the control group, patients will only receive usual care to prevent falls previously described above. In the intervention group, part of the usual care will be replaced, for 5 weeks, by supervised backward walking exercises, with the goal of doing two effective 10 minute backward walking sessions per week, without increasing the total time spent in rehabilitation.

The trial will be conducted under the intention-to-treat principle. Participants will have a clinical visit at day 0, at week 5 and at 6 months, during which clinical information and data related to their usual care and to the study will be collected. All participants will be followed for a total of 12 months, with monthly phone calls from a study team member to record any new falls, hospitalizations, health problems, or other important events. For 10 patients in the intervention group, an individual interview will also be carried out at the 5 week visit to better understand their experience of backward walking. 2 focus groups will be held with 2 randomly selected centers to identify barriers and facilitators to the implementation of backward walking sessions.

This study aims to determine whether adding backward walking to standard rehabilitation is a safe, acceptable and effective way to prevent falls in older adults at high risk of falling.

Przegląd badań

Status

Jeszcze nie rekrutacja

Szczegółowy opis

Justification: Falls are the leading cause of unintentional injuries in the population aged over 75 years in France. Backward walking training has so far been scarcely studied but appears to show promising results compared with conventional rehabilitation across multiple domains. It improves functional capacity, lower limb muscle strength, gait parameters, balance, and stability, all of which are key factors in reducing fall risk. Therefore, we hypothesize that a post-fall rehabilitation program incorporating backward walking sessions may reduce the incidence of falls over one year in high fallrisk risk patients aged over 75 years, compared with a standard rehabilitation program.

Primary objective: The primary objective of the study is to assess the impact of backward walking sessions on the incidence of falls at 1 year in patients aged over 75 years at high risk of falling and managed in a geriatric day hospital, compared with usual care in a geriatric day hospital.

Secondary objectives: The secondary objectives are to assess the effects of backward walking intervention, compared with usual care, on physical and psychological performance as balance, gait speed, functional mobility, fear of falling, and on the occurrence of falls and serious events (time to first fall, all-cause and fall-related hospitalizations, mortality). It also aims to evaluate medium- and long-term quality of life, functional independence, and all-cause hospitalizations, as well as the safety, acceptability, and feasibility of the intervention for patients and the day hospital team.

Settings: The sample size calculation was performed to detect a 35% reduction in the annual incidence rate of falls, assuming a control-group incidence of 1.4-3.6 falls per person-year and accounting for an anticipated 10% loss to follow-up. A total of 300 patients are expected to be enrolled over an 18 month inclusion period, with each patient followed for 12 months. Eleven geriatric centers will participate in the trial.

Experimental design: The PCRetro trial is an open-label, multicenter, randomized controlled, parallel-group clinical trial conducted in a geriatric day hospital rehabilitation setting. The study procedures are as follows: during the geriatric day hospital visit, the investigator will propose participation in the trial to eligible patients after verifying inclusion and exclusion criteria, and will subsequently obtain written informed consent. Patients will then be randomized to the control or intervention arm. Patients in the control arm will undergo two rehabilitation sessions per week for 12 weeks according to usual care. Patients in the intervention arm will undergo two rehabilitation sessions per week for 12 weeks according to usual care, combined with backward walking sessions over 5 weeks. In the intervention arm, backward walking will not increase the overall rehabilitation time but will replace part of usual care in order to achieve two effective 10-minute backward walking sessions per week. Patients will be followed in the same way regardless of their randomization arm, with a medical visit at week 5 and at month 6, and a monthly telephone call by a clinical research assistant blinded to the randomization allocation.

Practical procedures: A screening visit will first be conducted, during which clear and appropriate information about the study will be provided to the patient. This will be followed by an inclusion medical visit, during which written informed consent will be obtained, randomization will be performed, and clinical data as well as routine care data and additional data specific to the PCRetro study will be collected. Patients will then undergo rehabilitation either in the control group, receiving usual care in a geriatric day hospital, or in the intervention group, in which two backward walking activities per week will be integrated over a 5 week period in the usual care. Follow-up medical visits will be scheduled at week 5 and at month 6, during which routine care and additional PCRetro study data will again be collected. The occurrence of falls and intercurrent events will be monitored over 12 months through monthly telephone calls made by a clinical research technician. For 10 patients in the intervention group, a semi-structured interview will also be conducted during the week 5 visit. 2 focus groups will be held with 2 randomly selected centers to identify barriers and facilitators to the implementation of backward walking sessions.

Expected benefits: The primary anticipated benefit is a long-term reduction in the incidence of falls. In the short term, neuromuscular and postural improvements are expected, including increased lower limb muscle strength and better static and dynamic balance, which may translate into higher gait speed, improved functional mobility, and possibly reduced fear of falling. In the medium term, a potential decrease in hospitalization and mortality rates is anticipated. In the long term, these benefits could have a significant positive impact on the quality of life of patients and their caregivers.

Expected risks: No serious adverse events have been reported in studies of backward walking to date. Rare cases of increased joint pain, muscle soreness, and heightened fatigue have been described.

Statistical analysis: It will be conducted under the intention-to-treat principle, with data described and stratified by trial arm using appropriate descriptive statistics. The primary outcome will be analyzed using a Poisson model, with prespecified sensitivity analyses, including adjusted and per-protocol analyses based on a priori defined confounders identified via a Directed Acyclic Graph. Binary secondary outcomes will be summarized as odds ratios with 95% confidence intervals, while continuous secondary outcomes will be analyzed using parametric or non-parametric tests as appropriate. Time-to-event endpoints will be examined using Kaplan-Meier curves and Cox proportional hazards models, with results expressed as hazard ratios and 95% confidence intervals. Missing data will be handled in line with current recommendations and the predefined estimand framework. Qualitative data from focus groups and semi-structured interviews will be analyzed independently by two researchers using a Grounded Theory-inspired approach and interpreted within the Normalization Process Theory framework.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

300

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

      • Ivry-sur-Seine, Francja, 94205
        • Hôpital Charles-Foix
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • People aged over 75
  • Consultant at a geriatric day hospital
  • At high risk of falling. High risk of falling is defined in accordance with the World guidelines for falls prevention and management for older adults: a global initiative. The patient must have at least one of the following characteristics:

    • At least two falls in the last 12 months;
    • A fall resulting in an injury requiring medical attention;
    • Inability to get up unaided after a fall for at least one hour;
    • Suspected syncope;
    • Frailty (Clinical Frailty Scale ≥4)
  • Able to walk on a treadmill (physically able and capable of understanding the physiotherapist's instructions)
  • Able to understand and follow instructions from healthcare professionals
  • Patient or guardian who has been informed about the study and has given their free, informed and written consent to participate
  • Covered by a social security scheme (member or beneficiary) excluding Aide Médicale d'Etat (AME).

Exclusion Criteria:

  • Acute medical condition incompatible with prolonged standing (at the inclusion visit)
  • Estimated life expectancy of less than one year (at the inclusion visit)
  • Participation in another interventional trial or being within the exclusion period following a previous trial, where applicable (at the inclusion visit)
  • Balance disorders related to vestibular and cerebellar disorders (at the inclusion visit).

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Walking backwards
Standard care combined with rehabilitation sessions involving walking backwards. Ten rehabilitation sessions involving walking backwards are scheduled, at a rate of two sessions per week for five weeks, on a secure treadmill designed for walking backwards. Walking backwards will not add to the rehabilitation time; it will replace standard care to allow for two 10-minute sessions of actual walking backwards per week. Walking backwards are integrated to the 12 weeks standard program.
Aktywny komparator: Usual walking
The standard program runs for 12 weeks, with sessions twice a week, comprising two 45-minute activities per day. At least one session per week must include balance training, muscle strengthening and multi-modal exercises. The treadmill may be used for these activities, but only for walking forwards.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of falls per patient between inclusion and one year of follow-up including rehabilitation period in a geriatric day hospital
Ramy czasowe: 12 months after inclusion
Number of falls per patient
12 months after inclusion

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Balance assessment
Ramy czasowe: At inclusion, Week 5 and 6 months
Balance assessed using the Berg Scale
At inclusion, Week 5 and 6 months
Assessment of walking speed
Ramy czasowe: At inclusion, Week 5 and 6 months
Walking speed assessed using the 4-metre walk test
At inclusion, Week 5 and 6 months
Measuring fear of falling
Ramy czasowe: At inclusion, Week 5 and 6 months
Fear of falling measured using the Short Falls Efficacy Scale International (Short-FES-I)
At inclusion, Week 5 and 6 months
Assessment of functional mobility
Ramy czasowe: At inclusion, Week 5 and 6 months
Functional mobility assessed using the Time-up and Go test
At inclusion, Week 5 and 6 months
Time to first fall in days
Ramy czasowe: From inclusion to 12 months (monthly)
Telephone follow-up of the patient by a clinical research technician
From inclusion to 12 months (monthly)
Hospitalisation for any cause and due to a fall
Ramy czasowe: From inclusion to 12 mois (monthly)
Telephone follow-up of the patient by a clinical research technician
From inclusion to 12 mois (monthly)
Vital status
Ramy czasowe: From inclusion to 12 months (monthly)
Telephone follow-up of the patient by a clinical research technician
From inclusion to 12 months (monthly)
Quality of life score
Ramy czasowe: At inclusion, Week 5 and 6 months
Quality of life score will be assessed by the scale EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L scale)
At inclusion, Week 5 and 6 months
Assessment of independence
Ramy czasowe: At inclusion, Week 5 and 6 months
Independence measured using the ADL scale
At inclusion, Week 5 and 6 months
Assessment of independence
Ramy czasowe: At inclusion, Week 5 and 6 months
Independence measured using the iADL scale
At inclusion, Week 5 and 6 months
Assessment of user feedback
Ramy czasowe: At Week 5
User feedback measured using the F-SUS questionnaire (for the intervention arm only)
At Week 5
Intercurrent events
Ramy czasowe: At Week 1, Week 2, Week 3, Week 4, Week 5
Intercurrent events at home and any incidents, including the number of patients wishing to stop the sessions or withdraw from the trial during each session, measured at each session by a doctor or physiotherapist
At Week 1, Week 2, Week 3, Week 4, Week 5
Completion of 80% of sessions by at least 80% of enrolled patients
Ramy czasowe: At Week 5
Measurement taken during a consultation by a doctor
At Week 5
Assessment of satisfaction and acceptability of backward walking
Ramy czasowe: No later than 1 month after Week 5
Satisfaction and acceptability of backward walking assessed through 10 semi-structured individual interviews with included patients (intervention arm)
No later than 1 month after Week 5
Barriers and facilitators to the implementation of backward walking sessions
Ramy czasowe: No later than 1 month after the end of follow-up for the last patient included
Barriers and facilitators to the implementation of backward walking sessions identified during 2 focus groups with teams (doctors, nurses, physiotherapists, adapted physical activity (APA) professionals, occupational therapists and psychomotor therapists)
No later than 1 month after the end of follow-up for the last patient included

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Bruno OQUENDO, Dr, Hôpital Charles-Foix - Assistance Publique Hôpitaux de Paris

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

15 września 2026

Zakończenie podstawowe (Szacowany)

15 marca 2029

Ukończenie studiów (Szacowany)

15 marca 2029

Daty rejestracji na studia

Pierwszy przesłany

10 czerwca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

16 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 czerwca 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • APHP251245
  • 2025-A02896-43 (Inny identyfikator: ANSM)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.

Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Ramy czasowe udostępniania IPD

Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Kryteria dostępu do udostępniania IPD

Researchers who provide a methodologically sound proposal

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ICF

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Walking backwards

Subskrybuj